brigatinib: Clinical Trials

38 trials of brigatinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 6 recruiting, 5 active not recruiting, 5 unknown. 23 Phase 2, 8 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 223Completed 5, Recruiting 5, Withdrawn 5, Terminated 3, Unknown 3, Active not recruiting 2
Phase 18Completed 3, Active not recruiting 2, Recruiting 1, Terminated 1, Withdrawn 1
Phase 32Completed 2

Follow brigatinib: new trials by email Literature Review of brigatinib trials Research Report on brigatinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Using Tumor Models to Determine Treatments
Cobimetinib, Ponatinib, Brigatinib - Pancreatic Ductal Carcinoma, Advanced Cancer
Phase 2RecruitingUniversity Health Network, Toronto252025-04-072026-06-23
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
Brigatinib, Carboplatin, Pemetrexed - Non-small Cell Lung Cancer
Phase 2WithdrawnM.D. Anderson Cancer Center2024-12-112025-04-24
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Alectinib, Brigatinib, Lorlatinib 100 mg - NSCLC Stage IV, Sex Disorder
UnknownFondazione Policlinico Universitario Agostino Gemelli IRCCS802024-08-052024-08-09
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer
Brigatinib, Durvalumab - NSCLC, Stage III, ALK-rearrangement
Phase 2WithdrawnETOP IBCSG Partners Foundation2024-06-072024-10-08
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
Brigatinib - Non-small Cell Lung Cancer (NSCLC)
Active not recruitingTakeda1542024-01-172026-02-18
A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults
Brigatinib - Healthy Volunteers
Phase 1CompletedTakeda122023-12-202025-01-23
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
lorlatinib, crizotinib, brigatinib - Non-Small Cell Lung Cancer
CompletedPfizer52792023-06-232025-03-30
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Brigatinib - Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor
Phase 1 / Phase 2RecruitingPrincess Maxima Center for Pediatric Oncology652022-08-182025-12-05
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.
Brigatinib - Non-small Cell Lung Cancer
Phase 2UnknownYonsei University122022-06-012022-05-04
Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)
Brigatinib 180 MG, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer, ALK Gene Mutation
Phase 2Active not recruitingIntergroupe Francophone de Cancerologie Thoracique1102022-05-182025-11-17
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Crizotinib - Non-small Cell Lung Cancer
Phase 2RecruitingHunan Province Tumor Hospital902021-11-132024-09-20
Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
Brigatinib - Non-small Cell Lung Cancer (NSCLC)
RecruitingTakeda5002021-11-012026-03-17
Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)
Biopsy (tissue or liquid) - ALK Gene Mutation, NSCLC Stage IV
UnknownFondazione Policlinico Universitario Agostino Gemelli IRCCS1082021-07-122024-07-31
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
crizotinib, alectinib, brigatinib - ALK-positive NSCLC
CompletedPfizer5492020-12-142023-04-06
Brigatinib Before Brain Irradiation Trial (B3i Trial)
Brigatinib - Brain Metastases, Lung Cancer
Phase 2TerminatedUniversity of Colorado, Denver12020-11-172022-10-24
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer
Phase 2UnknownFondazione per la Medicina Personalizzata4002020-10-072023-10-03
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
Brigatinib, Brigatinib AAF - Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors
Phase 1 / Phase 2WithdrawnTakeda2020-09-012020-03-05
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Brigatinib, Neratinib, Retifanlimab - Neurofibromatosis Type 2, Vestibular Schwannoma
Phase 2RecruitingScott R. Plotkin, MD, PhD1092020-06-202026-11-12
Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays
Brigatinib - Non Small Cell Lung Cancer
Phase 2UnknownJI-YOUN HAN352020-05-152023-09-28
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
Brigatinib - Lung Cancer, NSCLC
Phase 2Active not recruitingFundación GECP332020-05-042026-02-04

Showing 20 of 38. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (23)  ·  Lung Neoplasms (9)  ·  Carcinoma (4)  ·  Lymphoma, Large-Cell, Anaplastic (4)  ·  Adenocarcinoma (2)  ·  Brain Neoplasms (2)  ·  Carcinoma, Large Cell (2)  ·  Carcinoma, Squamous Cell (2)  ·  Breast Neoplasms (1)  ·  Carcinoma, Pancreatic Ductal (1)  ·  Disease Progression (1)  ·  Ependymoma (1)  ·  Erectile Dysfunction (1)  ·  Eunuchism (1)  ·  Gastrointestinal Neoplasms (1)

Sponsors

Takeda (8)  ·  Ariad Pharmaceuticals (5)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2)  ·  Hunan Province Tumor Hospital (2)  ·  M.D. Anderson Cancer Center (2)  ·  Pfizer (2)  ·  City of Hope Medical Center (1)  ·  Criterium, Inc. (1)  ·  ETOP IBCSG Partners Foundation (1)  ·  Fondazione per la Medicina Personalizzata (1)  ·  Fox Chase Cancer Center (1)  ·  Fundación GECP (1)  ·  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)  ·  Intergroupe Francophone de Cancerologie Thoracique (1)  ·  JI-YOUN HAN (1)

Countries

United States (15)  ·  Italy (8)  ·  France (7)  ·  Spain (6)  ·  China (5)  ·  South Korea (5)  ·  Canada (4)  ·  Germany (4)  ·  Netherlands (4)  ·  Sweden (4)  ·  Austria (3)  ·  Hong Kong (3)  ·  Japan (3)  ·  Taiwan (3)  ·  Australia (2)

Top investigators

Yasir Y Elamin, MD (2)  ·  Yongchang Zhang, MD (2)  ·  Andrea Botticelli (1)  ·  Chad Rusthoven, MD (1)  ·  Collin Blakely, MD, PhD (1)  ·  Jessica J Lin (1)  ·  Mariano Provencio, MD (1)  ·  Michel Zwaan, Prof (1)

Results publications

PMID 29768119, PMID 41110382, PMID 23411383, PMID 27836716, PMID 28501139, PMID 30280657, PMID 31125274, PMID 32780660, PMID 33039599, PMID 33569983, PMID 34182952, PMID 34423676, PMID 36036294, PMID 36096442, PMID 36579743, PMID 37574132, PMID 38904277, PMID 39707229, PMID 41023484, PMID 41410381, PMID 41740899, PMID 41963505

NIH funding

2018 (4), 2015 (1), 2019 (1), P30CA016058 (1), P30CA046934 (1), P30CA060553 (1), U10CA180868 (1)